ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of ZIN ATI-001 in Advanced Melanoma

ZIOPHARM Oncology, Inc. ZIOP today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma. ZIN ATI-001 is the second clinical oncology product candidate from the ZIOPHARM-Intrexon Corporation exclusive synthetic biology channel partnership. The multi-center, single-arm, open-label, dose-escalation study, treating patients with unresectable Stage III or IV melanoma, will assess the safety and tolerability of intratumoral injections of ZIN ATI-001. Secondary endpoints include a determination of the recommended Phase 2 dose, an evaluation of T cell immunity markers, and preliminary anti-tumor activity.